OBJECTIVE： To observe the effectiveness and safety of different doses of rosuvastatin in the treatment of acute cerebral infarction. METHODS： Totally 120 patients with acute cerebral infarction were selected from Weifang Yidu Central Hospital during Jan. 2014-Dec. 2015， and then divided into observation group and control group according to admission order， with 60 cases in each group. Both groups received routine treatment as Shuxuening injection 10 mL，iv，1-2 times a day （or 20 mL added into 5％ Glucose injection 250-500 mL， ivgtt， qd）+Aspirin enteric-coated tablets 0.1 g，po，qd. Control group and observation group were additionally given Rosuvastatin calcium tablets 10 mg and 20 mg， po， qd （after supper）. Both groups were treated for 30 d. The levels of serum inflammatory factors （hs-CRP， TNF-α， IL-6）， blood lipid indexes （TC， TG， LDL-C）， neurological function and activity of daily life score were observed in 2 groups before and after treatment. The clinical efficacy and occurrence of ADR were recorded. RESULTS： Before treatment， there was no statistical significance in the levels of hs-CRP， TNF-α， IL-6， TC， TG and LDL-C， NIHSS scores and Barthel index （BI） scores between 2 groups （P＞0.05）. After treatment， the levels of hs-CRP， TNF-α， IL-6， TC， TG and LDL-C， NIHSS scores in 2 groups were decreased significantly， while BI scores were decreased significantly， observation group were significantly better than those of control group， with statistical significance （P＜0.05）. Total response rate of observation group （93.33％） was significantly higher than that of control group （86.67％）， with statistical significance （P＜0.05）. The incidence of ADR in observation group （23.33％） was significantly higher than control group （6.67％）， with statistical significance （P＜0.05）. CONCLUSIONS： Rosuvastatin can significantly reduce the inflammatory reaction and blood lipid level of patients with acute cerebral infarction， inhibit the formation of atherosclerotic plaque and improve prognosis. The large dose of rosuvastatin have better efficacy for acute cerebral infarction and can significantly improve the symptom of neurological deficits and daily living ability of patients.